Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
Diagnosticos da America paidR$0 Mil more to buy back shares than it received from issuing new shares.
It spentR$811 Mil paying down its debt.
It paidR$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spentR$0 Mil paying cash dividends to shareholders.
It spentR$1 Mil on other financial activities.
In all, Diagnosticos da AmericaspentR$812 Mil on financial activities for the
three
months ended in Mar. 2026.
Diagnosticos da America (BSP:DASA3) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Diagnosticos da America's issuance of stock for the
three
months ended in Mar. 2026 was R$0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Diagnosticos da America's repurchase of stock for the
three
months ended in Mar. 2026 was R$0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Diagnosticos da America's net issuance of debt for the
three
months ended in Mar. 2026 was R$-811 Mil.
Diagnosticos da America spentR$811 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Diagnosticos da America's net issuance of preferred for the
three
months ended in Mar. 2026 was R$0 Mil.
Diagnosticos da America paidR$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Diagnosticos da America's cash flow for dividends for the
three
months ended in Mar. 2026 was R$-0 Mil.
Diagnosticos da America spentR$0 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Diagnosticos da America's other financing for the
three
months ended in Mar. 2026 was R$-1 Mil.
Diagnosticos da America spentR$1 Mil on other financial activities.
Diagnosticos da America Cash Flow from Financing Related Terms
Diagnosticos da America Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Diagnosticos da America's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnosticos da America Cash Flow from Financing Chart
Diagnosticos da America Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Diagnosticos da America's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-3,107 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of R$-3,107 Mil mean?
Diagnosticos da America (BSP:DASA3) has a Cash Flow from Financing of R$-3,107 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Diagnosticos da America and its competitors.
Is Diagnosticos da America's Cash Flow from Financing too high?
Diagnosticos da America's current Cash Flow from Financing is R$-3,107 Mil. Overall, Diagnosticos da America has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnosticos da America's Cash Flow from Financing compare to TMO and DHR?
Diagnosticos da America's Cash Flow from Financing of R$-3,107 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Diagnostics & Research company?
A good Cash Flow from Financing depends on the Medical Diagnostics & Research industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Diagnosticos da America and its competitors. Diagnosticos da America's current Cash Flow from Financing is R$-3,107 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnosticos da America stock overvalued right now?
Based on GuruFocus' analysis, Diagnosticos da America (BSP:DASA3) is currently considered Significantly Overvalued. The stock's GF Value™ is R$1.69, compared to a current price of R$2.89 — trading 71% above its estimated fair value. The current Cash Flow from Financing is R$-3,107 Mil. Diagnosticos da America's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Diagnosticos da America (BSP:DASA3), the current Cash Flow from Financing is R$-3,107 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diagnosticos da America (BSP:DASA3) Overvalued in 2026?
Based on GuruFocus' analysis, Diagnosticos da America stock appears to be overvalued.
The current stock price of R$2.89 is trading 71% above its estimated GF Value™ of R$1.69.
GuruFocus considers Diagnosticos da America to be Significantly Overvalued.
Key valuation signals for BSP:DASA3:
Cash Flow from Financing: R$-3,107 Mil
GF Value™: R$1.69 vs. price of R$2.89 (71% above fair value)
No single metric tells the full story. See the BSP:DASA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diagnosticos da America SA operates as a medical diagnostics company in Brazil. The company offers clinical analysis, diagnostic imaging tests, and patient service centers. It has three operating segments. Outpatient care services and care coordination includes Diagnosis and health management, Hospitals and oncology include Medical and hospital services & Foreign operations include Diagnosis. The majority is from the Hospitals and oncology segment. Geographically, it operates in Brazil and South America (Argentina, Uruguay, Chile and Colombia).
46GF Score
Get the complete analysis for BSP:DASA3
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:DASA3 has been successfully added to your 
